Checkpoint inhibitors like Keytruda and Opdivo can be incredibly powerful drugs that kill cancer – it’s less than 70% of the time when it works. For years, scientists have been hoping to find a way to identify a combination of therapies that could help make these drugs work for a greater number of people.
New clinical trial results published in Science on Thursday provide some of the strongest evidence to date for an unusual but promising mashup: linking immunotherapy drugs to fecal microbiota transplants, or FMTs.
Unlock this article by subscribing to STAT + and enjoy your first 30 days for free!
START
What is it?
STAT + is the premium enrollment service of STAT for in-depth coverage and analysis of biotechnology, pharmaceutical, policy and life sciences. Our award-winning team covers news about Wall Street, policy developments in Washington, early scientific breakthroughs and results of clinical trials, and disruption of health care in Silicon Valley and beyond.
What is included?
- Daily reporting and analysis
- The most comprehensive operational coverage of a powerhouse of reporters
- Subscriber newsletters only
- Daily newsletters to inform you about the most important industry news of the day
- STAT + talks
- Weekly opportunities to engage with our reporters and leading industry experts
- Exclusive business opportunities
- Excellent access to networking events for networking across the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.